Please login to the form below

Not currently logged in
Email:
Password:

BACE inhibitor

This page shows the latest BACE inhibitor news and features for those working in and with pharma, biotech and healthcare.

Merck acquires pre-clinical biotech Calporta for up to $576m

Merck acquires pre-clinical biotech Calporta for up to $576m

Merck, among many big pharma players, has had its fair share of failure in the neurodegenerative research area – its lead BACE inhibitor verubecestat  failed to show a clinical effect in

Latest news

More from news
Approximately 3 fully matching, plus 22 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics